ESMO Congress | Conference

Novel Bispecific Antibody EX103 Demonstrates Safety, Elicits Preliminary Antitumor Activity in R/R B-Cell NHL

October 23rd 2023

The novel CD20xCD3 bispecific antibody EX103 displayed a favorable safety profile and produced preliminary antitumor activity in heavily pretreated patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Dato-DXd Provides PFS Benefit in HR+/HER2– Breast Cancer

October 23rd 2023

Datopotamab deruxtecan elicited a statistically significant and clinically meaningful improvement in progression-free survival vs chemotherapy for patients with hormone receptor-positive, HER2-low or -negative, metastatic breast cancer.

Lenvatinib/Pembrolizumab Combo Elicits Durable Responses in Advanced ccRCC

October 23rd 2023

Lenvatinib in combination with pembrolizumab led to tumor shrinkage and duration of response benefits compared with sunitinib across subgroups of interest in patients with advanced clear cell renal cell carcinoma.

Dr Cho on First-Line Amivantamab Plus Lazertinib in EGFR-Mutant NSCLC

October 23rd 2023

Byoung Chul Cho, MD, PhD, discusses key findings from the phase 3 MARIPOSA study of first-line amivantamab plus lazertinib vs osimertinib in EGFR-mutant locally advanced or metastatic non– small cell lung cancer.

Subgroup Analysis Shows Dostarlimab/Chemotherapy Elicits PFS Benefit in dMMR/MSI-H, TP53+, and NSMP Endometrial Cancer

October 23rd 2023

Patients with primary advanced or recurrent endometrial cancer whose disease was deficient mismatch repair/microsatellite instability-high, TP53 mutated, or had no specific molecular profile, experienced a survival benefit when treated with dostarlimab-gxly plus chemotherapy vs placebo plus chemotherapy.

Frontline Enfortumab Vedotin Plus Pembrolizumab Elicits OS Improvement in Advanced Urothelial Carcinoma

October 22nd 2023

Frontline treatment with the combination of enfortumab vedotin-ejfv and pembrolizumab led to a statistically significant improvement in overall survival vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma.

Cabozantinib Confers PFS Benefit in Previously Treated Advanced Neuroendocrine Tumors

October 22nd 2023

Patients with advanced neuroendocrine tumors who experienced progression following prior therapy experienced a significant improvement in terms of progression-free survival after treatment with cabozantinib compared with placebo.

Sotorasib Plus Panitumumab Extends PFS in Refractory KRAS G12C+ mCRC

October 22nd 2023

Treatment with combinations using sotorasib at multiple dose levels and panitumumab led to improved progression-free survival vs standard of care in patients with chemorefractory metastatic colorectal cancer harboring KRAS G12C mutations.

Induction Chemotherapy Prior to Chemoradiation Represents Potential New SOC in Locally Advanced Cervical Cancer

October 22nd 2023

Treatment with platinum-based chemotherapy prior to the administration of chemoradiation led to statistically significant improvements in progression-free survival and overall survival compared with chemoradiation alone in patients with locally advanced cervical cancer.

Tisotumab Vedotin Improves Survival in Recurrent/Metastatic Cervical Cancer

October 22nd 2023

Tisotumab vedotin led to a 30% reduction in the risk of death vs investigator’s choice of chemotherapy as second- or third-line therapy in patients with recurrent or metastatic cervical cancer with disease progression on doublet chemotherapy.

Trastuzumab Deruxtecan Has Clinically Meaningful Activity in Solid Tumors Harboring HER2 Mutations

October 22nd 2023

Fam-trastuzumab deruxtecan-nxki elicited responses that proved to be durable in patients with a range of solid tumors harboring HER2 mutations.

Dr Pietrantonio on the CodeBreak 300 Trial in KRAS G12C-mutated mCRC

October 22nd 2023

Filippo Pietrantonio, MD, discusses the influence of primary results from the phase 3 CodeBreak 300 trial of sotorasib plus panitumumab on KRAS G12C-mutated metastatic colorectal cancer.

Dr Chi on the MAGNITUDE Trial of Niraparib Plus Abiraterone in BRCA-Mutated mCRPC

October 22nd 2023

Kim N. Chi, MD, FRCPC, discusses data from the updated and final analysis of the phase 3 MAGNITUDE trial in BRCA-positive metastatic castration-resistant prostate cancer.

Frontline Nivolumab Plus Chemotherapy Boosts OS and PFS in Metastatic Urothelial Carcinoma

October 22nd 2023

Concurrent frontline nivolumab and gemcitabine-cisplatin followed by nivolumab maintenance therapy elicited OS and PFS benefits vs gemcitabine-cisplatin alone in patients with previously untreated, metastatic or unresectable urothelial carcinoma.

Niraparib Plus Abiraterone and Prednisone Elicits OS Benefit in BRCA1/2+ mCRPC

October 22nd 2023

The addition of niraparib to abiraterone acetate and prednisone led to a benefit in overall survival vs treatment with AAP alone in patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer.

Pembrolizumab Plus Enzalutamide Delivers No rPFS or OS Benefits in mCRPC

October 22nd 2023

Pembrolizumab plus enzalutamide provided no radiographic progression-free survival or overall survival improvements vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer.

Osimertinib Plus Chemo Improves CNS PFS in EGFR+ Advanced NSCLC With Baseline Brain Metastases

October 21st 2023

Osimertinib plus chemotherapy reduced the risk of central nervous system disease progression or death vs osimertinib alone in patients with locally advanced or metastatic EGFR-positive non–small cell lung cancer who had brain metastases at baseline, according to data from the phase 3 FLAURA2 trial.

Selpercatinib Significantly Improves PFS, Responses in Advanced RET+ Medullary Thyroid Cancer

October 21st 2023

Selpercatinib resulted in a statistically significant improvement in progression-free survival and overall response rate compared with cabozantinib or vandetanib in patients with advanced, multikinase inhibitor–naïve, RET-mutant medullary thyroid cancer, according to interim findings from the phase 3 LIBRETTO-531 trial.

Dr Girard on the Efficacy of First-Line Amivantamab Plus Chemotherapy in EGFR Exon 20 Insertion+ NSCLC

October 21st 2023

Nicolas Girard, MD, PhD, discusses primary efficacy results from the phase 3 PAPILLON trial of amivantamab plus chemotherapy in EGFR exon 20 insertion–mutated advanced non–small cell lung cancer.

Amivantamab Plus Chemotherapy Nearly Doubles PFS in EGFR Exon 20–Mutant NSCLC

October 21st 2023

The combination of amivantamab-vmjw (Rybrevant) and chemotherapy produced a median progression-free survival of 11.4 months vs 6.7 months with chemotherapy alone in patients with advanced, EGFR exon 20 insertion–positive non–small cell lung cancer.